Evidence map›Paper›PMID 40481885›Full record

ArticleJournal of molecular medicine (Berlin, Germany)2025

Serum proteins and faecal microbiota as potential biomarkers in newly diagnosed, treatment-naïve inflammatory bowel disease and irritable bowel syndrome patients.

Mario Matijašić, Anja Barešić, Hana Čipčić Paljetak, Mihaela Perić, Marina Panek, Ana Kunović, Dina Ljubas Kelečić, Darija Vranešić Bender, Katja Grubelić Ravić, Dunja Rogić and 6 more

Abstract read
In one paragraph

Article in Journal of molecular medicine (Berlin, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Wuji Pill andFrontiers in microbiology · 2026
    Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Mario MatijašićCenter for Translational and Clinical Research, University of Zagreb School of Medicine, Zagreb, Croatia.
Anja BarešićLaboratory for Computational Biology and Translational Medicine , Ruđer Bošković Institute, Zagreb, Croatia.ORCID https://orcid.org/0000-0003-1303-3031
Hana Čipčić PaljetakCenter for Translational and Clinical Research, University of Zagreb School of Medicine, Zagreb, Croatia. hana.paljetak@mef.hr.ORCID http://orcid.org/0000-0002-8837-3156
Mihaela PerićCenter for Translational and Clinical Research, University of Zagreb School of Medicine, Zagreb, Croatia.
Marina PanekCenter for Translational and Clinical Research, University of Zagreb School of Medicine, Zagreb, Croatia.
Ana KunovićUniversity of Zagreb School of Medicine, Zagreb, Croatia.
Dina Ljubas KelečićDepartment of Internal Medicine, Unit of Clinical Nutrition, University Hospital Centre Zagreb, Zagreb, Croatia.
Darija Vranešić BenderDepartment of Internal Medicine, Unit of Clinical Nutrition, University Hospital Centre Zagreb, Zagreb, Croatia.
Katja Grubelić RavićUniversity of Zagreb School of Medicine, Zagreb, Croatia.
Dunja RogićDepartment of Laboratory Diagnostics, University Hospital Centre Zagreb, Zagreb, Croatia.
Margareta AntolicDepartment of Laboratory Diagnostics, University Hospital Centre Zagreb, Zagreb, Croatia.
Ivana HorvatDepartment of Laboratory Diagnostics, University Hospital Centre Zagreb, Zagreb, Croatia.
Ivana KraljevićUniversity of Zagreb School of Medicine, Zagreb, Croatia.
Marko BanićUniversity of Zagreb School of Medicine, Zagreb, Croatia.
Željko KrznarićUniversity of Zagreb School of Medicine, Zagreb, Croatia.
Donatella VerbanacCenter for Translational and Clinical Research, University of Zagreb School of Medicine, Zagreb, Croatia.

Funding

European Regional Development Fund GA KK.01.1.1.01.0008Hrvatska Zaklada za Znanost DR-6-2014Hrvatska Zaklada za Znanost IP-11-2013-5467
6 · The paper itself

Abstract

Molecular biomarkers are valuable tools to predict the disease and determine its course. Several markers have been associated with inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS); however, none is sufficiently reliable to enable accurate diagnosis. We characterized a broad panel of serum proteins to assess disease-specific biomarker profiles and associate these findings with faecal microbiota composition in newly diagnosed IBD and IBS patients and healthy individuals. The study cohort consisted of 49 newly diagnosed treatment-naïve adult patients (13 Crohn's disease (CD), 13 ulcerative colitis (UC), and 23 IBS) and 12 healthy individuals. Inflammatory and metabolism-related serum proteins were assessed using PEA multiplex panels, while gut microbiota composition was determined by 16 s rRNA gene amplicon sequencing. Serum proteins AXIN1, TNFSF14, RNASE3, EN-RAGE, OSM, ST1A1, CA13 and NADK were identified as markers with the most promising specificity/sensitivity and predictivity between healthy and disease groups, while IL-17A and TNFRSF9 enabled differentiation between IBD and IBS patients. Increased abundance of Enterobacteriaceae was associated with protein markers significantly elevated in IBD/IBS. In contrast, depletion of beneficial taxa like Ruminococcaceae and Verucomicrobiaceae (i.e. Akkermansia muciniphila) was associated with decrease of a set of markers in diseased groups. Differences in the abundance of Turicibacteriaceae were more predictive to discern CD from UC than any of the serum proteins investigated. By using a broad panel of inflammation and metabolism-related proteins, we determined serum markers with significantly different levels in treatment-naïve IBD and IBS patients compared to healthy individuals, as well as between IBD and IBS. KEY MESSAGES : Significant changes in the levels of several serum proteins and abundances of faecal bacterial taxa between study groups were found. Increased levels of AXIN1, TNFSF14, RNASE3, EN-RAGE, OSM, ST1A1, CA13 and NADK characterize both IBD and IBS, while IL-17A and TNFRSF9 differentiate IBD from IBS. Increase of Enterobacteriaceae and depletion of beneficial taxa Ruminococcaceae and Verucomicrobiaceae (i.e. Akkermansia muciniphila) was found in IBD and IBS. Differences in Turicibacteriaceae were more predictive to discern CD from UC than any of the serum proteins investigated.

Indexed as

BiomarkersBlood ProteinsFecesGastrointestinal MicrobiomeInflammatory Bowel DiseasesIrritable Bowel SyndromeAdultCase-Control StudiesFemaleHumansMaleMiddle AgedYoung AdultBiomarkersBlood ProteinsCrohn’s diseaseFaecal microbiotaInflammatory bowel diseaseIrritable bowel syndromeSerum biomarkersTreatment-naïve patientsUlcerative colitis

Identifiers

PMID40481885
PMCPMC12343743

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.